MAPT and dementia: In conclusion, the biomarkers we investigated, Aβ42, total-tau, p-tau, and the t-tau/Aβ42, p-tau/Aβ42 ratios, can be used to differentiate AD dementia from other types of degenerated dementia patients, in early-onset subgroups.